NEXTURNBIOSCIENCE Co., LTD
089140 | KO
Overview
Corporate Details
- ISIN(s):
- KR7089140008
- LEI:
- Country:
- South Korea
- Address:
- 경기도 용인시 기흥구 기흥단지로121번길 35 (고매동), 용인시
- Website:
- http://www.nexturn.co.kr
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-26 00:00 |
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 9.5 KB | ||
| 2025-08-25 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
|
Korean | 107.5 KB | ||
| 2025-08-25 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
|
Korean | 69.6 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.5 MB | ||
| 2025-08-07 00:00 |
Share Issue/Capital Change
전환가액의조정
|
Korean | 10.1 KB | ||
| 2025-08-07 00:00 |
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 9.5 KB | ||
| 2025-08-01 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 86.1 KB | ||
| 2025-07-30 00:00 |
Share Issue/Capital Change
전환청구권행사
|
Korean | 9.1 KB | ||
| 2025-07-28 00:00 |
Share Issue/Capital Change
전환가액의조정
|
Korean | 10.7 KB | ||
| 2025-07-16 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(자기전환사채매도결정)
|
Korean | 62.7 KB | ||
| 2025-07-16 00:00 |
M&A Activity
주요사항보고서(회사합병결정)
|
Korean | 95.5 KB | ||
| 2025-07-16 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 6.0 KB | ||
| 2025-07-16 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.1 KB | ||
| 2025-07-16 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.7 KB | ||
| 2025-07-03 00:00 |
M&A Activity
합병등종료보고서(합병)
|
Korean | 21.8 KB |
Automate Your Workflow. Get a real-time feed of all NEXTURNBIOSCIENCE Co., LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for NEXTURNBIOSCIENCE Co., LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NEXTURNBIOSCIENCE Co., LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing Alpha DaRT, a precision alpha-radiation therapy designed to destroy solid tumors.
United States of America
DRTS
United States of America
DRTS
Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.
South Korea
196170
South Korea
196170
Develops small-molecule drug therapies for Alzheimer's, pain, and cognitive dysfunction.
Sweden
ALZCUR
Sweden
ALZCUR
Clinical-stage biotech developing immunology therapies for autoimmune and inflammatory diseases.
United States of America
ANAB
United States of America
ANAB
Develops anti-angiogenic therapeutics and foods for angiogenesis-related diseases.
South Korea
251280
South Korea
251280
Clinical-stage biotech developing CAR-T immunotherapies and vaccines to fight cancer.
United States of America
ANIX
United States of America
ANIX
Developing oral therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
United States of America
ANVS
United States of America
ANVS
United States of America
APDN
Developing precision cancer therapies targeting DNA Damage Response for solid tumors.
United States of America
APRE
United States of America
APRE
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea
397030
South Korea
397030